These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34878743)

  • 1. [COVID-19, anticoagulation and venous thromboembolism: what have we learned ?].
    Blondon M; Robert-Ebadi H
    Rev Med Suisse; 2021 Dec; 17(762):2140-2144. PubMed ID: 34878743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review.
    Cryer MJ; Farhan S; Kaufmann CC; Jäger B; Garg A; Krishnan P; Mehran R; Huber K
    Clin Appl Thromb Hemost; 2022; 28():10760296221074353. PubMed ID: 35068227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
    Kreidieh F; Temraz S
    Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis in COVID 2022: An Updated Narrative Review of Current Literature and Inpatient Management.
    Muthiah A; Ohnigian S; Reagan JL; Hsu A
    R I Med J (2013); 2022 Aug; 105(6):36-40. PubMed ID: 35881999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients: Meta-analysis of available literature.
    Aamir Waheed M; Rashid K; Rajab T; Rajab A; Adnan AH; Fayyaz H; Ibad AA; Basri R; Khan Y; Alhabib HI; Elzouki A
    Saudi Med J; 2022 Jun; 43(6):541-550. PubMed ID: 35675936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study.
    Poulakou G; Dimakakos E; Kollias A; Kyriakoulis KG; Rapti V; Trontzas I; Thanos C; Abdelrasoul M; Vantana T; Leontis K; Kakalou E; Argyraki K; Baraboutis I; Michelakis E; Giamarellos-Bourboulis E; Dimakou K; Tsoukalas G; Rapti A; Michelakis ED; Syrigos KN
    In Vivo; 2021; 35(1):653-661. PubMed ID: 33402523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection.
    Zanza C; Racca F; Longhitano Y; Piccioni A; Franceschi F; Artico M; Abenavoli L; Maiese A; Passaro G; Volonnino G; La Russa R
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33572570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies.
    Porres-Aguilar M; Mukherjee D; Didia SC; Lazo-Langner A
    Vascular; 2024 Feb; 32(1):220-225. PubMed ID: 36076354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia.
    Hsu A; Liu Y; Zayac AS; Olszewski AJ; Reagan JL
    Thromb Res; 2020 Dec; 196():375-378. PubMed ID: 32980620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art.
    Dimakakos E; Gomatou G; Catalano M; Olinic DM; Spyropoulos AC; Falanga A; Maraveyas A; Liew A; Schulman S; Belch J; Gerotziafas G; Marschang P; Cosmi B; Spaak J; Syrigos K;
    Anticancer Res; 2022 Jul; 42(7):3261-3274. PubMed ID: 35790272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients.
    Obi AT; Tignanelli CJ; Jacobs BN; Arya S; Park PK; Wakefield TW; Henke PK; Napolitano LM
    J Vasc Surg Venous Lymphat Disord; 2019 May; 7(3):317-324. PubMed ID: 30477976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.
    Tacquard C; Mansour A; Godon A; Godet J; Poissy J; Garrigue D; Kipnis E; Rym Hamada S; Mertes PM; Steib A; Ulliel-Roche M; Bouhemad B; Nguyen M; Reizine F; Gouin-Thibault I; Besse MC; Collercandy N; Mankikian S; Levy JH; Gruel Y; Albaladejo P; Susen S; Godier A;
    Chest; 2021 Jun; 159(6):2417-2427. PubMed ID: 33465342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Learning with COVID-19: what about anticoagulation?].
    Álvarez-Rodríguez E; González González R; Torres-Gárate R; López-Riquelme P; González Martil I; Abad Cuñado V
    An Sist Sanit Navar; 2020 Aug; 43(2):251-254. PubMed ID: 32865189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of venous thromboembolism in hospitalized patients with COVID-19.
    Spyropoulos AC
    Blood Adv; 2020 Aug; 4(16):4028. PubMed ID: 32841342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidance for anticoagulation management in venous thromboembolism during the coronavirus disease 2019 pandemic in Poland: an expert opinion of the Section on Pulmonary Circulation of the Polish Cardiac Society.
    Kosior DA; Undas A; Kopeć G; Hryniewiecki T; Torbicki A; Mularek-Kubzdela T; Windyga J; Pruszczyk P
    Kardiol Pol; 2020 Jun; 78(6):642-646. PubMed ID: 32515570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [COVID-19: Coagulopathy and thrombosis].
    Tazi Mezalek Z
    Rev Med Interne; 2021 Feb; 42(2):93-100. PubMed ID: 33509669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19.
    Ortega-Paz L; Galli M; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):E15-E17. PubMed ID: 35108396
    [No Abstract]   [Full Text] [Related]  

  • 18. [Coagulopathies, thrombotic risk and anticoagulation in COVID-19].
    Peters P; Sprynger M; Lancellotti P; Oury C
    Rev Med Liege; 2020 Sup; 75(S1):86-93. PubMed ID: 33211428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.
    Cuker A; Tseng EK; Nieuwlaat R; Angchaisuksiri P; Blair C; Dane K; Davila J; DeSancho MT; Diuguid D; Griffin DO; Kahn SR; Klok FA; Lee AI; Neumann I; Pai A; Righini M; Sanfilippo KM; Siegal D; Skara M; Terrell DR; Touri K; Akl EA; Bou Akl I; Bognanni A; Boulos M; Brignardello-Petersen R; Charide R; Chan M; Dearness K; Darzi AJ; Kolb P; Colunga-Lozano LE; Mansour R; Morgano GP; Morsi RZ; Muti-Schünemann G; Noori A; Philip BA; Piggott T; Qiu Y; Roldan Y; Schünemann F; Stevens A; Solo K; Wiercioch W; Mustafa RA; Schünemann HJ
    Blood Adv; 2021 Oct; 5(20):3951-3959. PubMed ID: 34474482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
    Bikdeli B; Garcia DA
    Ann Intern Med; 2022 Feb; 175(2):JC17. PubMed ID: 35099994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.